AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00805935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone in oil
Description: 50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
Study NCT00805935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone in oil
Description: 50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
Study NCT00805935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate
Description: Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.
Study NCT00805935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.
Study NCT01013233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: cognitive training over 6 weeks, consist of 6 meetings (a 45minutes), three sessions focus on concentration tasks and three sessions on memory problems.
Study NCT01013233 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: no intervention
Study NCT02574871 — intervention group
Intervention type: OTHER
Intervention: Psychological and biological data collection
Description: Psychological and biological data collection for identification of the chronic stress presence
Study NCT04209309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Study NCT04209309 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Study NCT00590954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home.~In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4.
Study NCT00072150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT01040585 — intervention group
Intervention type: DRUG
Intervention: Linezolid
Description: Treatment for VAP as indication approved and as physician criterium.
Study NCT00749723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa, carboplatin, etoposide
Description: high dose chemotherapy followed by to autologous stem cell transplantation
Study NCT00749723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide, thiotepa
Description: high dose chemotherapy followed by autologous stem cell transplantation
Study NCT04441333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AspivixTM cervical vacuum tenaculum
Description: Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum
Study NCT02030171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: functionnal reeducation
Description: Specific functionnal reeducation for chronic low back pain
Study NCT02531997 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotic Relaxation Therapy
Description: There are 3 induction scripts that build upon each other, each about 20 minutes in length. The first focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second focuses more on body image related to sexuality, sexual desire, passion, and romanticism. The third includes suggestions from the previous inductions, but adds a behavior that the woman chooses to incorporate for the last 2 weeks of the intervention. A digital recording will be provided of the intervention content for home practice.
Study NCT02531997 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Progressive Muscle Relaxation
Description: Women will be instructed how to do progressive relaxation and will be given the opportunity to ask questions and express concerns. The research therapist will utilize a script to focus the conversation on relaxation and planning the implementation of the behavior. Participants will be given a digital recording of 4 pleasant background sounds to facilitate their relaxation practice. Home practice will be encouraged.
Study NCT01691404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epicatechin
Description: Subjects will be asked to consume supplements containing 100mg of epicatechin daily
Study NCT01691404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin
Description: Subjects will be asked to consume 160mg of quercetin-3-glucoside daily
Study NCT01691404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be asked to consume capsules containing placebo (cellulose) daily
Study NCT00257556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menotrophin
Description: 150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
Study NCT00257556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa
Description: 150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
Study NCT01933048 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FluMist
Description: FluMist Intranasal Vaccine
Study NCT01933048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluMist
Description: FluMist Intranasal Vaccine
Study NCT00380393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK malaria vaccine 257049 Vaccine
Description: 3 dose intramuscular injection
Study NCT00380393 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine
Description: 3 dose intramuscular injection
Study NCT03126994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PhysioWave Cardiovascular Analyzer
Description: Measurement of Pulse Wave Velocity, Pulse Rate, Body Weight and BMI
Study NCT00749723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation
Description: autologous stem cell transplantation following HD-chemotherapy
Study NCT03126994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtCor XCEL PWA & PWV
Description: Measurement of Pulse Wave Velocity and Pulse Rate
Study NCT03126994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Detecto SOLO
Description: Measurement of Body Weight and BMI
Study NCT02353767 — intervention group
Intervention type: PROCEDURE
Intervention: Noninvasive evaluation of liver fibrosis and steatosis
Description: Transient elastography (using the Fibroscan, CAP Fibroscan) and biomarker panels (FibroTest, Fibromètre, Hepascore, Steatotest, Nashtest)
Study NCT01707914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese bayberry juice
Description: Consume 500 mL CBJ/d (250 mL CBJ twice daily)
Study NCT01707914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02967250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Description: Subjects will be provided \~50mg/kg/day (based on the use of 250 and 500mg capsules) of UDCA to be divided into 3 equal daily doses and titrated up over \~2 weeks to a stable dose for 4 weeks.
Study NCT02478138 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel lymph node mapping
Description: Thirty (30) patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system (Pinpoint, Novadaq, Waterloo ON). After the study, patients will continue with their planned management.
Study NCT02478138 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green (ICG)
Study NCT02478138 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: near-infrared fluorescence (NIR) imaging (Pinpoint, Novadaq, Waterloo)
Study NCT01723163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence Reinforcement Therapy (ART)
Description: Veterans randomized to the intervention will receive cognitive-behavioral telephone counseling (TC), a tele-medicine clinic for access to nicotine replacement (NRT), and mobile contingency management (mCM)
Study NCT01723163 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Counseling and NRT
Description: Veterans randomized to the control group will receive cognitive-behavioral telephone counseling (TC) and a tele-medicine clinic for access to nicotine replacement (NRT)
Study NCT00749723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraventricular etoposide
Description: prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (>3m to \<3y 0.7 mg; >3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years
Study NCT01403038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix Dose Regimen 1 for 84 days
Study NCT01403038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix Dose Regimen 2 for 84 days
Study NCT01403038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix Dose Regimen 3 for 84 days
Study NCT01403038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix Dose Regimen 4 for 84 days Other interventions may be added
Study NCT01403038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix Dose Regimen 5 for 84 days
Study NCT01403038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix Dose Regimen 6 for 84 days
Study NCT01403038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elagolix
Description: Elagolix plus Activella Dose Regimen 7 for 84 days
Study NCT02582853 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Lumbar puncture for spinal fluid
Study NCT02582853 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Sample
Description: Blood sample
Study NCT00749723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trofosfamide, etoposide
Description: maintenance therapy: trofosfamide and etoposide: 100 mg/m²/d and 25 mg/m²/d, respectively, for 21 days every 4 weeks. Number of cycles: until progression or maximum up to 2 years
Study NCT04174690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Force platform
Description: In order to volunteers to be selected for collection a recruitment test will be taken, the volunteer will have to stand on one foot for 5 seconds without additional support. So that the volunteer can go to the balance test on the force platform, he will be dressed with safety equipment (harness), and will also have the attachment of the electrodes.
Study NCT04240574 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Debritom
Description: hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.
Study NCT01709370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole, PD 0332991
Study NCT04287907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitor Group
Description: Use of colorimetric end tidal CO2 to guide provider during provision of mask ventilation, where colour change indicates effective breaths
Study NCT02510794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations.
Study NCT02510794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations.
Study NCT01606046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vapocoolant spray
Description: spray for 5 seconds from a distance of 30 cm just before the needle EMG
Study NCT01606046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical anesthetic cream
Description: application of EMLA cream on the needle electrode insertion site 60 minutes before the needle EMG
Study NCT04206618 — intervention group
Intervention type: DRUG
Intervention: Teriparatide
Description: 1 subcutaneous injection daily for 12 months
Study NCT04206618 — intervention group
Intervention type: DRUG
Intervention: Denosumab
Description: 1 subcutaneous injection every 6 months for 12 months
Study NCT03529006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sequent Please inflation
Description: PCI procedure for treatment of ISR with DEB - Sequent Please - inflation
Study NCT03529006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorb BVS implantation
Description: PCI procedure for treatment of ISR with Absorb BVS implantation
Study NCT01681394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenol-rich cocoa extract
Description: 250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
Study NCT01681394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chocolate cream
Study NCT01779089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg po bid for 6 months
Description: Minocycline 100 mg po bid or placebo for 6 months
Study NCT01779089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00123500 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Diet
Study NCT00123500 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Physical Activity
Study NCT00123500 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Environment
Description: Environment
Study NCT00123500 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Control Group
Study NCT02338089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 100 micromolar solution
Study NCT06722404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapeutic foods
Description: All children were initially fed F-75 (75 kcal/ 100mL) therapeutic milk (Phase I) and then progressed to F-100 (100 kcal/ 100mL) (Phase II) and Plumpy'nuts (F-100 in spread form with iron fortification) (Phase III) with follow-up for 48 days
Study NCT06722404 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Therapeutic foods plus Synbiotics
Description: the intervention group received therapeutic foods plus synbiotics containing Oligomate that was fortified in F75 at the rate of 7.5 g/L containing 4.1 g/L GOS for 1 g/100 kcal dose and at the rate of 11.5 g/L containing 6.1 g/L GOS for 1.5 g/100 kcal dose while in F100 and Plumpy'nuts it was fortified at the rate of 10 g/L containing 5.5 g/L GOS for 1 g/100 kcal dose and at the rate of 15 g/L containing 8.25 g/L GOS for 1.5 g/100 kcal dose and Resiton (Lactobacillus paracasei sbsp. paracasei) 3 billion cfu/day and 6 billion cfu/day that were mixed in different combinations.
Study NCT02879825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Group-A patients, with mitral valve prolapse but no mitral regurgitation, will undergo specifically for research purposes a cardiac MRI, 24-hour external loop recording and exercise ECG on top of regular echocardiography evaluation.~Realization of these examinations will be performed according to recommendations for patients with mitral regurgitation (groups B, C and D)
Study NCT03315572 — intervention group
Intervention type: OTHER
Intervention: Interviewer administered version of ease of use items
Description: The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.
Study NCT03315572 — intervention group
Intervention type: OTHER
Intervention: Self-administered version of ease of use items
Description: The interview will be self-administered by subjects aged 8 to 11 years.
Study NCT03315572 — intervention group
Intervention type: OTHER
Intervention: Caregiver version of ease of use items
Description: Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.
Study NCT01318408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Titration of Keppra will start at 250 mg by mouth twice daily for three days. Then 500 mg by mouth twice daily for three days. Then 750 mg by mouth twice daily for the duration of the study, or for as long as treatment is necessary. This titration schedule is subject to change based on subject's tolerability.
Study NCT01699165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal filter
Description: Active nasal filter
Study NCT01699165 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo nasal filter
Description: Placebo nasal filter
Study NCT01631994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: 1 tablet of 10mg of oral dissolving metoclopramide will be taken by patient 45 minutes prior to ingestion of the capsule.
Study NCT04666896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored home-based exercise therapy
Description: exercises were divided into four types: 1) shrug exercises; 2) external rotation exercises; 3) bench slides; and 4) wall slides.
Study NCT04666896 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard home-based exercise therapy
Description: The exercise program consisted of 4 types of exercises for training 1) balance and proprioception; 2) isometric strength; 3) rotator cuff muscles; and 4) open chain elevation
Study NCT03787550 — intervention group
Intervention type: DRUG
Intervention: The Sedatives, analgesics and antibiotics
Description: The sedatives (dexmedetomidine, midazolam, propofol), analgesics (butorphanol, remifentanil, sufentanil), and six antibiotics (linezolid, voriconazole, tigecycline, teicoplanin, caspofungin and meropenem) will be used according to the clinical need.
Study NCT00714415 — intervention group
Intervention type: DRUG
Intervention: BeneFIX
Description: Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study NCT04014985 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: An extensive biological assessment
Description: To study the morphology of red blood cells, the markers of oxidative stress and the signaling pathway of IFGF1.
Study NCT03271502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia
Description: Total intravenous anesthesia with propofol and remifentanil
Study NCT03271502 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation anesthesia
Description: Inhalation anesthesia with sevoflurane and remifentanil
Study NCT02150447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton pump inhibitor
Description: Lansoprazole 30 mg, daily
Study NCT01280643 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT04439591 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Computerised cognitive training
Description: A 12-week bi-weekly group-based computerised cognitive training programme conducted in community centres
Study NCT04439591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerised cognitive training
Description: A 12-week bi-weekly group-based computerised cognitive training programme conducted in community centres
Study NCT02548585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously.
Study NCT02150447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, daily
Study NCT01156103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: America SCORES, Bay Area
Description: After-school program promoting physical activity via soccer 3 days/week
Study NCT02548585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously.